Pharmaceuticals, Biotechnology and Life Sciences
Avacta Group said on Monday that the first major immunogenicity study of Affimer technology using human ex-vivo samples was successful with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin.
Verona Pharma’s non-executive director Patrick Humphrey has decided to retire from the Board, effective April 15, 2017. The company said it doesn’t plan replacing him.
The drugstore chain Walgreens is taking a three-pronged approach to combat the public health crisis stemming from prescription opioids, according to a team of pharmacists and other clinicians from the company.
The Food and Drug Administration (FDA) has advised consumers not to purchase or use African Viagra, a product promoted for sexual enhancement.
U.S. Food and Drug Administration (FDA) has granted regular approval to AstraZeneca’s osimertinib (Tagrisso), for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.
DBV Technologies, the Geneva University Hospitals (HUG) and BioNet-Asia have announced results from a Phase I trial assessing Viaskin rPT`s ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet`s recombinant pertussis toxin.
Invictus MD Strategies Corp.,Canada’s cannabis company, said Thursday it will move its shares from the Canadian Securities Exchange and be listed on TSX Venture Exchange, where it starts trading on March 31, 2017.
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.
Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has reported its audited annual results for the year ended December 31, 2016.